Latest news with #Progyny
Yahoo
4 days ago
- Business
- Yahoo
Progyny Adds Distinguished Healthcare Executive Elizabeth Bierbower to Board of Directors
NEW YORK, May 29, 2025 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a global leader in women's health and family building solutions, today announced the addition of healthcare veteran Elizabeth Bierbower to its Board of Directors. "As we continue to round out our board's experience, Elizabeth's extensive leadership with some of the largest health plans and deep financial expertise will be invaluable as we scale and innovate across the women's health and family building spectrum," said Pete Anevski, CEO of Progyny. "Her insights will support our strategy to deliver even more value to our members, clients, and shareholders as we expand our reach and impact." Bierbower brings more than 30 years of experience in the healthcare industry, having held leadership roles across health plans, provider services, and care innovation. She most recently served as Chairman and CEO of Friday Health Plans and held various senior positions at Humana, including Segment President, President of the Employer Group Segment, and Chief Operating Officer of the Specialty Benefits division. Prior to Humana, she held leadership roles at Highmark Blue Cross Blue Shield and Coventry Health Care. Bierbower's depth of healthcare experience also includes serving on the board of directors of numerous companies including Option Care Health, the largest national independent provider for infusion therapy, as well as the boards of several privately held companies, including BlueSprig, Quest Analytics, Paradigm Corp., and Point32Health. 'Progyny is setting the standard for what comprehensive, outcomes-based women's health and family building benefits should look like in today's workforce,' said Bierbower. 'I'm joining the board at an exciting time as the company continues its expansion of both products and reach, and I look forward to contributing to the team's objective of advancing access to high-quality care for women and families.' For more information about Progyny and its Board of Directors, please visit About ProgynyProgyny (Nasdaq: PGNY) is a global leader in women's health and family building solutions, trusted by the nation's leading employers, health plans and benefit purchasers. We envision a world where everyone can realize their dreams of family and ideal health. Our outcomes prove that comprehensive, inclusive, and intentionally designed solutions simultaneously benefit employers, patients, and physicians. Our benefits solution empowers patients with concierge support, coaching, education, and digital tools; provides access to a premier network of fertility and women's health specialists who use the latest science and technologies; drives optimal clinical outcomes; and reduces healthcare costs. Headquartered in New York City, Progyny has been recognized for its leadership and growth as a TIME100 Most Influential Company, CNBC Disruptor 50, Modern Healthcare's Best Places to Work in Healthcare, Forbes' Best Employers, Financial Times Fastest Growing Companies, Inc. 5000, Inc. Power Partners, and Crain's Fast 50 for NYC. For more information, visit For Further Information, Please Contact: Investors:James Hartinvestors@ Media:Alexis Fordmedia@ in to access your portfolio
Yahoo
19-05-2025
- Business
- Yahoo
Q1 Earnings Outperformers: Progyny (NASDAQ:PGNY) And The Rest Of The Health Insurance Providers Stocks
Looking back on health insurance providers stocks' Q1 earnings, we examine this quarter's best and worst performers, including Progyny (NASDAQ:PGNY) and its peers. Upfront premiums collected by health insurers lead to reliable revenue, but profitability ultimately depends on accurate risk assessments and the ability to control medical costs. Health insurers are also highly sensitive to regulatory changes and economic conditions such as unemployment. Going forward, the industry faces tailwinds from an aging population, increasing demand for personalized healthcare services, and advancements in data analytics to improve cost management. However, continued regulatory scrutiny on pricing practices, the potential for government-led reforms such as expanded public healthcare options, and inflation in medical costs could add volatility to margins. One big debate among investors is the long-term impact of AI and whether it will help underwriting, fraud detection, and claims processing or whether it may wade into ethical grey areas like reinforcing biases and widening disparities in medical care. The 11 health insurance providers stocks we track reported a strong Q1. As a group, revenues beat analysts' consensus estimates by 3% while next quarter's revenue guidance was in line. Amidst this news, share prices of the companies have had a rough stretch. On average, they are down 8.4% since the latest earnings results. Pioneering a data-driven approach to family building that has achieved an industry-leading patient satisfaction score of +80, Progyny (NASDAQ:PGNY) provides comprehensive fertility and family building benefits solutions to employers, helping employees access quality fertility treatments and support services. Progyny reported revenues of $324 million, up 16.5% year on year. This print exceeded analysts' expectations by 5%. Overall, it was a satisfactory quarter for the company with an impressive beat of analysts' sales volume estimates. 'We're pleased with the strong start to the year, highlighted by both our solid financial results as well as the progress made with our investments to expand the platform and extend our leading position as the solution of choice in women's health and family building,' said Pete Anevski, Chief Executive Officer of Progyny. Progyny delivered the weakest full-year guidance update of the whole group. Unsurprisingly, the stock is down 10% since reporting and currently trades at $21.03. Is now the time to buy Progyny? Access our full analysis of the earnings results here, it's free. With over 9,000 retail pharmacy locations serving as neighborhood health destinations across America, CVS Health (NYSE:CVS) operates retail pharmacies, provides pharmacy benefit management services, and offers health insurance through its Aetna subsidiary. CVS Health reported revenues of $94.59 billion, up 7% year on year, outperforming analysts' expectations by 1.5%. The business had an exceptional quarter with an impressive beat of analysts' same-store sales estimates and a solid beat of analysts' EPS estimates. Although it had a fine quarter compared to its peers, the market seems unhappy with the results as the stock is down 6.5% since reporting. It currently trades at $62.36. Is now the time to buy CVS Health? Access our full analysis of the earnings results here, it's free. With over 100 million people served across its various businesses and a workforce of more than 400,000, UnitedHealth Group (NYSE:UNH) operates a health insurance business and Optum, a healthcare services division that provides everything from pharmacy benefits to primary care. UnitedHealth reported revenues of $109.6 billion, up 9.8% year on year, falling short of analysts' expectations by 1.7%. It was a softer quarter as it posted a significant miss of analysts' full-year EPS guidance estimates and a slight miss of analysts' EPS estimates. UnitedHealth delivered the weakest performance against analyst estimates in the group. The company added 395,000 customers to reach a total of 54.12 million. As expected, the stock is down 50.9% since the results and currently trades at $287.66. Read our full analysis of UnitedHealth's results here. Founded in 2013 with a mission to transform healthcare for seniors, Alignment Healthcare (NASDAQ:ALHC) provides Medicare Advantage health plans for seniors with features like concierge services, transportation benefits, and technology-driven care coordination. Alignment Healthcare reported revenues of $926.9 million, up 47.5% year on year. This number beat analysts' expectations by 4.4%. Overall, it was a very strong quarter as it also put up a solid beat of analysts' EPS estimates. Alignment Healthcare achieved the fastest revenue growth among its peers. The company added 28,400 customers to reach a total of 217,500. The stock is down 10.2% since reporting and currently trades at $15.00. Read our full, actionable report on Alignment Healthcare here, it's free. With roots dating back to 1792 and serving millions of customers across the globe, The Cigna Group (NYSE:CI) provides healthcare services through its Evernorth Health Services and Cigna Healthcare segments, offering pharmacy benefits, specialty care, and medical plans. Cigna reported revenues of $65.5 billion, up 14.4% year on year. This result surpassed analysts' expectations by 8.4%. More broadly, it was a satisfactory quarter as it also recorded a decent beat of analysts' EPS estimates but a significant miss of analysts' customer base estimates. Cigna scored the biggest analyst estimates beat among its peers. The company lost 1.14 million customers and ended up with a total of 16.36 million. The stock is down 5.3% since reporting and currently trades at $317. Read our full, actionable report on Cigna here, it's free. Thanks to the Fed's rate hikes in 2022 and 2023, inflation has been on a steady path downward, easing back toward that 2% sweet spot. Fortunately (miraculously to some), all this tightening didn't send the economy tumbling into a recession, so here we are, cautiously celebrating a soft landing. The cherry on top? Recent rate cuts (half a point in September 2024, a quarter in November) have propped up markets, especially after Trump's November win lit a fire under major indices and sent them to all-time highs. However, there's still plenty to ponder — tariffs, corporate tax cuts, and what 2025 might hold for the economy. Want to invest in winners with rock-solid fundamentals? Check out our 9 Best Market-Beating Stocks and add them to your watchlist. These companies are poised for growth regardless of the political or macroeconomic climate. Join Paid Stock Investor Research Help us make StockStory more helpful to investors like yourself. Join our paid user research session and receive a $50 Amazon gift card for your opinions. Sign up here. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
17-05-2025
- Business
- Yahoo
There May Be Reason For Hope In Progyny's (NASDAQ:PGNY) Disappointing Earnings
The most recent earnings report from Progyny, Inc. (NASDAQ:PGNY) was disappointing for shareholders. Despite the soft profit numbers, our analysis has optimistic about the overall quality of the income statement. We check all companies for important risks. See what we found for Progyny in our free report. Many investors haven't heard of the accrual ratio from cashflow, but it is actually a useful measure of how well a company's profit is backed up by free cash flow (FCF) during a given period. To get the accrual ratio we first subtract FCF from profit for a period, and then divide that number by the average operating assets for the period. The ratio shows us how much a company's profit exceeds its FCF. Therefore, it's actually considered a good thing when a company has a negative accrual ratio, but a bad thing if its accrual ratio is positive. That is not intended to imply we should worry about a positive accrual ratio, but it's worth noting where the accrual ratio is rather high. To quote a 2014 paper by Lewellen and Resutek, "firms with higher accruals tend to be less profitable in the future". Over the twelve months to March 2025, Progyny recorded an accrual ratio of -0.70. That indicates that its free cash flow quite significantly exceeded its statutory profit. In fact, it had free cash flow of US$196m in the last year, which was a lot more than its statutory profit of US$52.5m. Progyny shareholders are no doubt pleased that free cash flow improved over the last twelve months. That might leave you wondering what analysts are forecasting in terms of future profitability. Luckily, you can click here to see an interactive graph depicting future profitability, based on their estimates. As we discussed above, Progyny's accrual ratio indicates strong conversion of profit to free cash flow, which is a positive for the company. Because of this, we think Progyny's underlying earnings potential is as good as, or possibly even better, than the statutory profit makes it seem! Unfortunately, though, its earnings per share actually fell back over the last year. Of course, we've only just scratched the surface when it comes to analysing its earnings; one could also consider margins, forecast growth, and return on investment, among other factors. Ultimately, this article has formed an opinion based on historical data. However, it can also be great to think about what analysts are forecasting for the future. At Simply Wall St, we have analyst estimates which you can view by clicking here. This note has only looked at a single factor that sheds light on the nature of Progyny's profit. But there are plenty of other ways to inform your opinion of a company. Some people consider a high return on equity to be a good sign of a quality business. While it might take a little research on your behalf, you may find this free collection of companies boasting high return on equity, or this list of stocks with significant insider holdings to be useful. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
12-05-2025
- Business
- Yahoo
Progyny, Inc. to Present at BofA Securities 2025 Health Care Conference
NEW YORK, May 12, 2025 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a global leader in women's health and family building solutions, today announced that Progyny's Chief Executive Officer, Pete Anevski, and Chief Financial Officer, Mark Livingston, will participate in a fireside chat at the BofA Securities 2025 Health Care Conference on Wednesday, May 14, 2025, at 3:00 P.M. Pacific Time / 6:00 P.M. Eastern Time. A live audiocast and replay will be available from the Events and Presentations section of Progyny's website at About Progyny Progyny (Nasdaq: PGNY) is a global leader in women's health and family building solutions, trusted by the nation's leading employers, health plans and benefit purchasers. We envision a world where everyone can realize their dreams of family and ideal health. Our outcomes prove that comprehensive, inclusive, and intentionally designed solutions simultaneously benefit employers, patients and physicians. Our benefits solution empowers patients with concierge support, coaching, education, and digital tools; provides access to a premier network of fertility and women's health specialists who use the latest science and technologies; drives optimal clinical outcomes; and reduces healthcare costs. Headquartered in New York City, Progyny has been recognized for its leadership and growth as a TIME100 Most Influential Company, CNBC Disruptor 50, Modern Healthcare's Best Places to Work in Healthcare, Forbes' Best Employers, Financial Times Fastest Growing Companies, Inc. 5000, Inc. Power Partners, and Crain's Fast 50 for NYC. For more information, visit For Further Information, Please Contact:Investors:James Hartinvestors@ Media:Alexis Fordmedia@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
12-05-2025
- Business
- Yahoo
Progyny, Inc. to Present at BofA Securities 2025 Health Care Conference
NEW YORK, May 12, 2025 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a global leader in women's health and family building solutions, today announced that Progyny's Chief Executive Officer, Pete Anevski, and Chief Financial Officer, Mark Livingston, will participate in a fireside chat at the BofA Securities 2025 Health Care Conference on Wednesday, May 14, 2025, at 3:00 P.M. Pacific Time / 6:00 P.M. Eastern Time. A live audiocast and replay will be available from the Events and Presentations section of Progyny's website at About Progyny Progyny (Nasdaq: PGNY) is a global leader in women's health and family building solutions, trusted by the nation's leading employers, health plans and benefit purchasers. We envision a world where everyone can realize their dreams of family and ideal health. Our outcomes prove that comprehensive, inclusive, and intentionally designed solutions simultaneously benefit employers, patients and physicians. Our benefits solution empowers patients with concierge support, coaching, education, and digital tools; provides access to a premier network of fertility and women's health specialists who use the latest science and technologies; drives optimal clinical outcomes; and reduces healthcare costs. Headquartered in New York City, Progyny has been recognized for its leadership and growth as a TIME100 Most Influential Company, CNBC Disruptor 50, Modern Healthcare's Best Places to Work in Healthcare, Forbes' Best Employers, Financial Times Fastest Growing Companies, Inc. 5000, Inc. Power Partners, and Crain's Fast 50 for NYC. For more information, visit For Further Information, Please Contact:Investors:James Hartinvestors@ Media:Alexis Fordmedia@
